-
Effect of hormonal therapies for prostate cancer on cognition: The ongoing search for clarity Cancer (IF 6.2) Pub Date : 2024-03-16 Guillaume Lim Fat, Shabbir Alibhai
Hormonal therapy for advanced prostate cancer with androgen deprivation and novel androgen‐receptor axis–targeted therapy have produced mixed results on cognitive effects in previous studies. The most robust meta‐analysis to date shows a lack of objective cognitive changes across all domains at 6 months of treatment, although significant patient‐perceived, subjective decline suggests that concerns
-
Cyclin‐dependent kinase inhibitors enhance programmed cell death protein 1 immune checkpoint blockade efficacy in triple‐negative breast cancer by affecting the immune microenvironment Cancer (IF 6.2) Pub Date : 2024-03-14 Jiayi Wu, Wei Wang, Lu Gao, Xiying Shao, Xiaojia Wang
BackgroundClinical studies on programmed death‐ligand 1 (PD‐L1) immune checkpoint inhibitors for treating triple‐negative breast cancer (TNBC) have shown unsatisfactory efficacy due to low tumor‐infiltrating lymphocyte (TIL) levels. Inhibitors targeting cyclin‐dependent kinase (CDK) proteins can affect the immune microenvironment, increase TIL levels, and promote antitumor immunity, thus providing
-
PEC‐PRO: A new prognostic score from a series of 87 patients with localized perivascular epithelioid cell neoplasms (PEComas) treated with curative intent Cancer (IF 6.2) Pub Date : 2024-03-12 Justine Gantzer, Maud Toulmonde, François Severac, Ali N. Chamseddine, Céline Charon‐Barra, Charles Vinson, Alice Hervieu, Agathe Bourgmayer, François Bertucci, Thomas Ryckewaert, Thibaud Valentin, Nelly Firmin, Loïc Chaigneau, Emmanuelle Bompas, Philippe Follana, Nathalie Rioux‐Leclercq, Pauline Soibinet‐Oudot, Laurence Bozec, François Le Loarer, Noëlle Weingertner, Christine Chevreau, Florence Duffaud
BackgroundPerivascular epithelioid cell neoplasms (PEComas) encompass a heterogeneous family of mesenchymal tumors. Previously described clinicopathologic features aimed at distinguishing benign from malignant variants but lacked prognostic value.MethodsThis retrospective analysis examined clinicopathologic data from patients who had localized PEComa across French Sarcoma Network centers. The authors
-
Outcome of patients with relapsed or refractory nonrhabdomyosarcoma soft tissue sarcomas enrolled in phase 2 cooperative group clinical trials: A report from the Children’s Oncology Group Cancer (IF 6.2) Pub Date : 2024-03-12 Sapna Oberoi, Amira Qumseya, Wei Xue, Rajkumar Venkatramani, Aaron R. Weiss
BackgroundThe aim of this study was to estimate the event‐free survival (EFS) of children and young adults with relapsed or refractory nonrhabdomyosarcoma soft tissue sarcoma (NRSTS) treated in nonrandomized phase 2 studies conducted by the Children’s Oncology Group (COG) and predecessor groups to establish a benchmark EFS for future phase 2 NRSTS trials evaluating the activity of novel agents.MethodsA
-
Venetoclax plus a hypomethylating agent versus cytarabine, aclarubicin, and granulocyte colony‐stimulating factor chemotherapy as a first‐line therapy for newly diagnosed acute myeloid leukemia: A propensity score–matched analysis Cancer (IF 6.2) Pub Date : 2024-03-12 Rui Huang, Honghua He, Xiaoli Xu, Xiaonan Lin, Ying Dong, Xiaotao Wang, Fang Jiang, Pengcheng Huang, Shuyi Mo, Zhenqian Huang, Yaya Wang, Hongfang Tao, Yaling Zheng, Ming Wu, Chuting Yang, Ziyu Zheng, Ying Zhao, Yuming Zhang, Yuhua Li
BackgroundBoth venetoclax plus a hypomethylating agent (VEN/HMA) and cytarabine, aclarubicin, and granulocyte colony‐stimulating factor (CAG) are low‐intensity regimens for older patients with acute myeloid leukemia (AML) that show good efficacy and safety. It is unknown how VEN/HMA compares with the CAG regimen for the treatment of newly diagnosed AML.MethodsThe outcomes of patients with newly diagnosed
-
Improving lifestyle behaviors during chemotherapy for breast cancer: The Lifestyle, Exercise, and Nutrition Early After Diagnosis (LEANer) Trial Cancer (IF 6.2) Pub Date : 2024-03-12 Leah S. Puklin, Leah M. Ferrucci, Maura Harrigan, Courtney McGowan, Michelle Zupa, Brenda Cartmel, Fang‐Yong Li, Jennifer A. Ligibel, Donna Spiegelman, Mona Sharifi, Tara Sanft, Melinda L. Irwin
BackgroundLittle is known about improving physical activity (PA) and diet during and after chemotherapy for breast cancer. This secondary analysis examines changes in PA and diet quality during a yearlong intervention for patients with breast cancer undergoing chemotherapy and evaluates factors associated with these changes.MethodsNewly diagnosed patients with breast cancer (N = 173) undergoing chemotherapy
-
The changing landscape of small cell lung cancer Cancer (IF 6.2) Pub Date : 2024-03-12 Giordano Fabricio Cittolin‐Santos, Brendan Knapp, Bharath Ganesh, Feng Gao, Saiama Waqar, Thomas Eldridge Stinchcombe, Ramaswamy Govindan, Daniel Morgensztern
BackgroundSmall‐cell lung cancer (SCLC) is characterized by rapid proliferation and early dissemination. The objective of this study was to examine the demographic trends and outcomes in SCLC.MethodsThe authors queried the National Cancer Institute's Surveillance, Epidemiology, and End Results database to assess the trends in incidence, demographics, staging, and survival for SCLC from 1975 to 2019
-
The association of metabolic syndrome scores trajectory patterns with risk of all cancer types Cancer (IF 6.2) Pub Date : 2024-03-11 Li Deng, Tong Liu, Chen‐An Liu, Qi Zhang, Meng‐Meng Song, Shi‐Qi Lin, Yi‐Ming Wang, Qing‐Song Zhang, Han‐Ping Shi
BackgroundMetabolic syndrome (MetS) elevates cancer risk. However, a single MetS assessment does not fully reveal the long‐term association with cancer. Inflammation, alongside MetS, could synergistically expedite both the onset and advancement of cancer. This study aims to investigate MetS score trajectories and cancer risk in a large, prospective cohort study.MethodsThe authors prospectively examined
-
Cardiotoxicity of breast cancer drugs requires additional monitoring Cancer (IF 6.2) Pub Date : 2024-03-07 Mary Beth Nierengarten
A new study that examined the cardiotoxicity of a range of breast cancer drugs underscores the need for clinicians to be vigilant in monitoring patients who are taking these drugs for cardiovascular adverse effects. In the study, investigators reviewed the current literature on studies documenting the clinical manifestations of cardiotoxicities associated with the different classes of drugs used to
-
2023 American Society of Hematology meeting roundup Cancer (IF 6.2) Pub Date : 2024-03-07 Mary Beth Nierengarten
This news section offers Cancer readers timely information on events, public policy analysis, topical issues, and personalities. In this issue, results from several studies presented at the 2023 American Society of Hematology meeting roundup show patient improvement based on adding a new element to standard therapies. In addition, new study results underscore the need to closely monitor patients who
-
-
Routine estradiol testing recommended for women at high risk of breast cancer Cancer (IF 6.2) Pub Date : 2024-03-07 Mary Beth Nierengarten
Routinely measuring blood hormone levels, particularly estradiol levels, in women who are at high risk for breast cancer may help to identify which women will benefit from prophylactic treatment with aromatase inhibitors. This is a key takeaway from a study in which researchers looked at the effects of serum hormone levels on the efficacy of anastrozole in preventing breast cancer in high-risk postmenopausal
-
Attitudes toward the American Cancer Society’s 2020 cervical cancer screening guidelines: A qualitative study of a national sample of US clinicians Cancer (IF 6.2) Pub Date : 2024-03-04 Alexandra D. Michel, Holly B. Fontenot, Lindsay Fuzzell, Naomi C. Brownstein, Paige Lake, Susan T. Vadaparampil, Rebecca B. Perkins
BackgroundThe 2020 American Cancer Society (ACS) guidelines are the most recent national guidelines for cervical cancer screening. These guidelines propose two major changes from current practice: initiating screening at age 25 years and using primary human papillomavirus (HPV) testing. Adoption of guidelines often occurs slowly, and therefore understanding clinician attitudes is important to facilitate
-
Reply to “Mismatch repair and microsatellite instability—Recommendation for an optimal test strategy” Cancer (IF 6.2) Pub Date : 2024-03-02 Courtney J. Riedinger, Ashwini Esnakula, Paulina J. Haight, Adrian A. Suarez, Wei Chen, Jessica Gillespie, Alyssa Villacres, Alexis Chassen, David E. Cohn, Paul J. Goodfellow, Casey M. Cosgrove
-
Mismatch repair and microsatellite instability—Recommendation for an optimal test strategy Cancer (IF 6.2) Pub Date : 2024-03-02 Josef Rüschoff, Wolfgang Dietmaier, Tina Bocker Edmonston, Reinhard Büttner
-
Secondary analysis of late major gastrointestinal and genitourinary toxicities in unfavorable‐risk prostate cancer patients receiving docetaxel: Insights from a randomized trial Cancer (IF 6.2) Pub Date : 2024-03-01 Tyler Walburn, Ming‐Hui Chen, Marian Loffredo, Elizabeth McMahon, Peter F. Orio, Paul L. Nguyen, Anthony V. D’Amico, Mutlay Sayan
BackgroundThis study sought to evaluate the late toxicity associated with neoadjuvant and concurrent docetaxel and radiation therapy in patients with prostate cancer.MethodsA secondary analysis was performed of the phase 3 multicenter randomized trial (Dana‐Farber Cancer Institute 05‐043) including 350 patients with nonmetastatic unfavorable‐risk prostate cancer. Patients were randomized 1:1 to receive
-
An ultrasound‐based nomogram for predicting axillary node pathologic complete response after neoadjuvant chemotherapy in breast cancer: Modeling and external validation Cancer (IF 6.2) Pub Date : 2024-03-01 Qijun Zheng, Huicui Yan, Yingjian He, Jiwei Wang, Nan Zhang, Ling Huo, Yiqiang Liu, Lize Wang, Ling Xu, Zhaoqing Fan
IntroductionThe staging and treatment of axillary nodes in breast cancer have become a focus of research. For breast cancer patients with fine‐needle aspiration—or core needle biopsy—confirmed positive nodes, axillary lymph node dissection (ALND) after neoadjuvant chemotherapy (NAC) is still a standard treatment. However, some patients achieve an axillary pathologic complete response (pCR) after NAC
-
A tale of two pathways: Review of immune checkpoint inhibitors in DNA mismatch repair‐deficient and microsatellite instability‐high endometrial cancers Cancer (IF 6.2) Pub Date : 2024-02-29 Ying L. Liu, Britta Weigelt
The DNA mismatch repair (MMR) pathway is critical for correcting DNA mismatches generated during DNA replication. MMR‐deficiency (MMR‐D) leads to microsatellite instability (MSI) associated with an increased mutation rate, driving cancer development. This is particularly relevant in endometrial cancer (EC) as 25%–30% of tumors are of MMR‐D/MSI‐high (MSI‐H) phenotype. Comprehensive assessment using
-
The expanding role of circulating tumor DNA in resectable non–small cell lung cancer Cancer (IF 6.2) Pub Date : 2024-02-29 Daniel Morgensztern
Despite treatment with curative intent, many patients with non–small cell lung cancer develop tumor relapse. The detection of minimal residual disease with circulating tumor DNA may allow for a more personalized treatment, which may potentially allow patients with a high risk for relapse to receive more aggressive therapy and those with a low risk for relapse to avoid overtreatment.
-
Detection of circulating tumor DNA with ultradeep sequencing of plasma cell‐free DNA for monitoring minimal residual disease and early detection of recurrence in early‐stage lung cancer Cancer (IF 6.2) Pub Date : 2024-02-29 Aaron C. Tan, Gillianne G. Y. Lai, Stephanie P. L. Saw, Kevin L. M. Chua, Angela Takano, Boon‐Hean Ong, Tina P. T. Koh, Amit Jain, Wan Ling Tan, Quan Sing Ng, Ravindran Kanesvaran, Tanujaa Rajasekaran, Ekaterina Kalashnikova, Derrick Renner, Sumedha Sudhaman, Meenakshi Malhotra, Himanshu Sethi, Minetta C. Liu, Alexey Aleshin, Wan‐Teck Lim, Eng‐Huat Tan, Anders J. Skanderup, Mei‐Kim Ang, Daniel S. W
BackgroundIn early‐stage non–small cell lung cancer (NSCLC), recurrence is frequently observed. Circulating tumor DNA (ctDNA) has emerged as a noninvasive tool to risk stratify patients for recurrence after curative intent therapy. This study aimed to risk stratify patients with early‐stage NSCLC via a personalized, tumor‐informed multiplex polymerase chain reaction (mPCR) next‐generation sequencing
-
Triple‐negative breast cancer survival prediction using artificial intelligence through integrated analysis of tertiary lymphoid structures and tumor budding Cancer (IF 6.2) Pub Date : 2024-02-29 Xupeng Hou, Xueyang Li, Yunwei Han, Hua Xu, Yongjie Xie, Tianxing Zhou, Tongyuan Xue, Xiaolong Qian, Jiazhen Li, Hayson Chenyu Wang, Jingrui Yan, Xiaojing Guo, Ying Liu, Jing Liu
BackgroundTriple‐negative breast cancer (TNBC) is a highly heterogeneous and clinically aggressive disease. Accumulating evidence indicates that tertiary lymphoid structures (TLSs) and tumor budding (TB) are significantly correlated with the outcomes of patients who have TNBC, but no integrated TLS‐TB profile has been established to predict their survival. The objective of this study was to investigate
-
Phase 1b/2 study of penpulimab (AK105), an antiprogrammed cell death‐1 immunoglobulin G1 antibody, in advanced or metastatic solid tumors (AK105‐204) Cancer (IF 6.2) Pub Date : 2024-02-27 Yulong Zheng, Jianqing Zhu, Jianping Xiong, Ou Jiang, Hong Wang, Yanru Xie, Yuefen Zhou, Nong Xu
BackgroundPenpulimab, a new‐generation antiprogrammed cell death‐1 immunoglobulin G1 monoclonal antibody, was engineered to optimize receptor occupancy and eliminate fragment crystallizable γ‐mediated effector function. In this multicenter, phase 1b/2, multicohort study, the objective was to investigate the efficacy, safety, and immunogenicity of penpulimab in advanced solid tumors.MethodsPatients
-
Dual CTLA‐4 and PD‐1 checkpoint blockade using CS1002 and CS1003 (nofazinlimab) in patients with advanced solid tumors: A first‐in‐human, dose‐escalation, and dose‐expansion study Cancer (IF 6.2) Pub Date : 2024-02-26 Sarwan Bishnoi, Dusan Kotasek, Morteza Aghmesheh, Thomas Yau, Rasha Cosman, Amy Prawira, Maggie Moore, Stephen L. Chan, Andrew Mant, Richard Eek, Robert Zielinski, Rila Su, Zhaoxuan Pan, Yiding Ma, Fei Li, Peiqi Li, Archie N. Tse
BackgroundThis study investigated the safety and efficacy of an anti–CTLA‐4 monoclonal antibody (CS1002) as monotherapy and in combination with an anti–PD‐1 monoclonal antibody (CS1003) in patients with advanced/metastatic solid tumors.MethodsThe phase 1 study involved phase 1a monotherapy dose‐escalation (part 1) and phase 1b combination therapy dose escalation (part 2) and expansion (part 3). Various
-
Reappraisal of prognostic factors used in the European Pediatric Soft Tissue Sarcoma Study Group RMS 2005 study for localized rhabdomyosarcoma to optimize risk stratification and generate a prognostic nomogram Cancer (IF 6.2) Pub Date : 2024-02-24 Gian Luca De Salvo, Paola Del Bianco, Veronique Minard-Colin, Julia Chisholm, Meriel Jenney, Gabriela Guillen, Christine Devalck, Rick Van Rijn, Janet Shipley, Daniel Orbach, Anna Kelsey, Timothy Rogers, Florent Guerin, Giovanni Scarzello, Andrea Ferrari, Maja Cesen Mazic, Johannes H. M. Merks, Gianni Bisogno
The objective of this study was to investigate the role of clinical factors together with FOXO1 fusion status in patients with nonmetastatic rhabdomyosarcoma (RMS) to develop a predictive model for event-free survival and provide a rationale for risk stratification in future trials.
-
Employment outcomes of adolescent and young adult (AYA) cancer survivors and their partners: A Dutch population-based study Cancer (IF 6.2) Pub Date : 2024-02-23 Polle W. Dankers, Silvie H. M. Janssen, Mies van Eenbergen, Bettina M. Siflinger, Winette T. A. van der Graaf, Olga Husson
The aim of this population-based registry study was to examine the impact of cancer on employment outcomes in adolescent and young adult (AYA) survivors and their partners and associated sociodemographic and clinical characteristics.
-
The 340B Program and oral specialty drugs for advanced prostate cancer Cancer (IF 6.2) Pub Date : 2024-02-23 Kassem S. Faraj, Samuel R. Kaufman, Mary Oerline, Lindsey A. Herrel, Avinash Maganty, Megan E. V. Caram, Vahakn B. Shahinian, Brent K. Hollenbeck
Expensive oral specialty drugs for advanced prostate cancer can be associated with treatment disparities. The 340B program allows hospitals to purchase medications at discounts, generating savings that can improve care of the socioeconomically disadvantaged. This study assessed the effect of hospital 340B participation on advanced prostate cancer.
-
FDA authorizes blood test for risk assessment of hereditary cancers Cancer (IF 6.2) Pub Date : 2024-02-24 Mary Beth Nierengarten
In September 2023, the Food and Drug Administration (FDA) granted marketing authorization for a new hereditary cancer test. Called the Invitae Common Hereditary Cancers Panel, the test is the first of its kind to go through FDA review. The test panel includes 48 genes linked to hereditary forms of cancer. The genes analyzed are mainly those associated with adult-onset cancers such as gastrointestinal
-
First person profile: Betty Ferrell, PhD, RN Cancer (IF 6.2) Pub Date : 2024-02-24 Mary Beth Nierengarten
This news section offers Cancer readers timely information on events, public policy analysis, topical issues, and personalities. In this issue, Betty Ferrell, PhD, RN, reflects on her career, built on a belief that palliative care should be offered from the beginning of a cancer diagnosis rather than only as an end‐of‐life therapy. In addition, capivasertib with fulvestrant is now available in the
-
FDA approves capivasertib with fulvestrant for breast cancer Cancer (IF 6.2) Pub Date : 2024-02-24 Mary Beth Nierengarten
A new treatment approach is now available in the United States for select patients with advanced breast cancer for whom previous treatments have failed. In November 2023, the Food and Drug Administration (FDA) approved the use of capivasertib with fulvestrant for patients who have hormone receptor–positive, human epidermal growth factor receptor 2–negative locally advanced or metastatic breast cancer
-
-
Erratum to “Patient‐reported outcomes with cemiplimab monotherapy for first‐line treatment of advanced non–small cell lung cancer with PD‐L1 of ≥50%: The EMPOWER‐Lung 1 study” Cancer (IF 6.2) Pub Date : 2024-02-24
This erratum corrects the following: Gümüş M, Chen C-I, Ivanescu C, et al. Patient-reported outcomes with cemiplimab monotherapy for first-line treatment of advanced non–small cell lung cancer with PD-L1 of ≥50%: The EMPOWER-Lung 1 study. Cancer. 2023;129(1):118-129. doi:10.1002/cncr.34477 Following the publication of this article, the authors wish to correct the following minor transcribing errors
-
Treatment and outcomes of clear cell sarcoma of the kidney: A report from the Children's Oncology Group studies AREN0321 and AREN03B2 Cancer (IF 6.2) Pub Date : 2024-02-24 Daniel J. Benedetti, Lindsay A. Renfro, Ian Tfirn, Najat C. Daw, John A. Kalapurakal, Peter F. Ehrlich, Geetika Khanna, Elizabeth Perlman, Anne Warwick, Kenneth W. Gow, Arnold C. Paulino, Nita L. Seibel, Paul Grundy, Conrad V. Fernandez, James I. Geller, Elizabeth A. Mullen, Jeffrey S. Dome
BackgroundOn the fifth National Wilms Tumor Study, treatment for clear cell sarcoma of the kidney (CCSK) included combined vincristine, doxorubicin, cyclophosphamide, and etoposide (regimen I) plus radiation therapy (RT), yielding 5‐year event‐free survival (EFS) rates of 100%, 88%, 73%, and 29% for patients who had with stage I, II, III, and IV disease, respectively. In the Children’s Oncology Group
-
SWOG S1820: A pilot randomized trial of the Altering Intake, Managing Bowel Symptoms Intervention in Survivors of Rectal Cancer Cancer (IF 6.2) Pub Date : 2024-02-22 Virginia Sun, Katherine A. Guthrie, Tracy E. Crane, Kathryn B. Arnold, Sarah Colby, Sarah G. Freylersythe, Christa Braun‐Inglis, Roxanne Topacio, Craig A. Messick, Joseph C. Carmichael, Andrew A. Muskovitz, Mohammed Nashawaty, Madhuri Bajaj, Stacey A. Cohen, Devin C. Flaherty, Mark A. O’Rourke, Lee Jones, Robert S. Krouse, Cynthia A. Thomson
BackgroundSurvivors of rectal cancer experience persistent bowel dysfunction after treatments. Dietary interventions may be an effective approach for symptom management and posttreatment diet quality. SWOG S1820 was a pilot randomized trial of the Altering Intake, Managing Symptoms in Rectal Cancer (AIMS‐RC) intervention for bowel dysfunction in survivors of rectal cancer.MethodsNinety‐three posttreatment
-
The impact of cancer metastases on COVID-19 outcomes: A COVID-19 and Cancer Consortium registry-based retrospective cohort study Cancer (IF 6.2) Pub Date : 2024-02-20 Cecilia A. Castellano, Tianyi Sun, Deepak Ravindranathan, Clara Hwang, Nino Balanchivadze, Sunny R. K. Singh, Elizabeth A. Griffiths, Igor Puzanov, Erika Ruiz-Garcia, Diana Vilar-Compte, Ana I. Cárdenas-Delgado, Rana R. McKay, Taylor K. Nonato, Archana Ajmera, Peter P. Yu, Rajani Nadkarni, Timothy E. O’Connor, Stephanie Berg, Kim Ma, Dimitrios Farmakiotis, Kendra Vieira, Panos Arvanitis, Renee M. Saliby
COVID-19 can have a particularly detrimental effect on patients with cancer, but no studies to date have examined if the presence, or site, of metastatic cancer is related to COVID-19 outcomes.
-
Shortened telomere length in peripheral blood leukocytes is associated with cumulative radioactive iodine doses in patients with differentiated thyroid carcinoma Cancer (IF 6.2) Pub Date : 2024-02-20 Hoonsung Choi, Sun Wook Cho, Hwan Hee Kim, Ka Hee Yi, Do Joon Park, Young Joo Park
BackgroundTelomere length is associated with cancer risk and cancer aggressiveness. Radioactive iodine (RAI) therapy for thyroid cancer has raised concerns for second primary malignancy (SPM) in patients with high cumulative doses. The association between RAI dose and peripheral blood leukocyte telomere length was examined.MethodsA total of 425 patients were included who underwent total thyroidectomy
-
Risk factors for neurocognitive impairment, emotional distress, and poor quality of life in survivors of pediatric rhabdomyosarcoma: A report from the Childhood Cancer Survivor Study Cancer (IF 6.2) Pub Date : 2024-02-19 Ellen van der Plas, Himani Darji, Deo K. Srivastava, Melissa Schapiro, Donna Jeffe, Stephanie Perkins, Rebecca Howell, Wendy Leisenring, Gregory T. Armstrong, Kevin Oeffinger, Kevin Krull, Kim Edelstein, Robert J. Hayashi
BackgroundPrevalence and risk of poor psychological outcomes following rhabdomyosarcoma (RMS) are not well‐established.MethodsParticipants in this cross‐sectional, case‐control study (n = 713 survivors, 42.5% female; mean [SD] age, 30.5 [6.6] years; n = 706 siblings, 57.2% female; mean age, 32.8,[7.9] years) completed measures of neurocognition, emotional distress, and health‐related quality of life
-
Myelofibrosis: Current unmet needs, emerging treatments, and future perspectives Cancer (IF 6.2) Pub Date : 2024-02-19 Claire N. Harrison, Jean‐Jacques Kiladjian, Steffen Koschmieder, Francesco Passamonti
The current standard‐of‐care for treatment of myelofibrosis (MF) comprises inhibitors of the Janus kinase (JAK)/signal transducers and activators (STAT) pathway; however, despite their ability to alleviate symptoms, they do not appear to modify underlying disease and have not demonstrated substantial survival benefit. Allogeneic‐hematopoietic stem cell transplantation remains the only curative option
-
Revolutionizing cancer treatment in India: Evaluating the unmet need, economics, and a roadmap for project implementation of particle therapy Cancer (IF 6.2) Pub Date : 2024-02-19 Anil Gupta, V. Subramani, Rishabh Kumar, Rafi Kareem, Bhaskar Vishwanathan, Daya Nand Sharma
-
Characterizing the burden of biliary tract cancers across 28 hospitals in Ontario, Canada Cancer (IF 6.2) Pub Date : 2024-02-15 Woo Jin Choi, Surain Roberts, Amol Verma, Fahad Razak, Grainne M. O’Kane, Steven Gallinger, Gideon Hirschfield, Bettina Hansen, Gonzalo Sapisochin
The incidence of biliary tract cancers (BTC) appears to be increasing worldwide. We analyzed the characteristics of BTC-related hospitalizations under medical services across 28 hospitals in Ontario, Canada.
-
SWOG 1609 cohort 48: anti–CTLA-4 and anti–PD-1 for advanced gallbladder cancer Cancer (IF 6.2) Pub Date : 2024-02-15 Sandip P. Patel, Elizabeth Guadarrama, Young Kwang Chae, Michael J. Dennis, Benjamin C. Powers, Chih-Yi Liao, William A. Ferri, Thomas J. George, Elad Sharon, Christopher W. Ryan, Megan Othus, Gabby Lopez, Charles D. Blanke, Razelle Kurzrock
Most patients with advanced gallbladder cancer are treated with multiagent chemotherapy. Immune checkpoint inhibitors offer the possibility of a durable response with less toxicity. This prospective, multicenter, open-label study was designed to evaluate the anticancer activity of nivolumab plus ipilimumab in patients with advanced gallbladder cancer.
-
Coronary artery calcium and cardiovascular outcomes in patients with lymphoma undergoing autologous hematopoietic cell transplantation Cancer (IF 6.2) Pub Date : 2024-02-15 Stephanie Wu, June-Wha Rhee, Aleksi Iukuridze, Alysia Bosworth, Sitong Chen, Liezl Atencio, Venkat Manubolu, Rusha Bhandari, Faizi Jamal, Matthew Mei, Alex Herrera, Fatima Rodriguez, Stephen Forman, Ryotaro Nakamura, F. Lennie Wong, Matthew Budoff, Saro H. Armenian
Patients undergoing autologous hematopoietic cell transplantation (HCT) have a >2-fold risk of developing cardiovascular disease (CVD; heart failure, myocardial infarction, and stroke), compared to the general population. Coronary artery calcium (CAC) is predictive of CVD in nononcology patients but is not as well studied in patients who underwent HCT and survivors of HCT.The objective of this study
-
Discovery of a proliferation essential gene signature and actin-like 6A as potential biomarkers for predicting prognosis and neoadjuvant chemotherapy response in triple-positive breast cancer Cancer (IF 6.2) Pub Date : 2024-02-15 Xiaofen Li, Shiping Luo, Wenfen Fu, Mingyao Huang, Xiewei Huang, Shaohong Kang, Jie Zhang, Qingshui Wang, Chuangui Song
Patients with triple-positive breast cancer (TPBC) have a higher risk of recurrence and lower survival rates than patients with other luminal breast cancers. However, there are few studies on the predictive biomarkers of prognosis and treatment responses in TPBC.
-
-
Updated American Cancer Society lung cancer screening guidelines Cancer (IF 6.2) Pub Date : 2024-02-15 Mary Beth Nierengarten
This news section offers Cancer readers timely information on events, public policy analysis, topical issues, and personalities. In this issue, updated American Cancer Society lung cancer screening guidelines focus on expanded criteria based on age, smoking status, and smoking history. In addition, one new study finds that telehealth visits for cancer care grew continuously from 2020 to 2021 without
-
Continuous expansion of telehealth in cancer care Cancer (IF 6.2) Pub Date : 2024-02-15 Mary Beth Nierengarten
Telehealth visits for cancer care grew continuously from 2020 to 2021 without any evidence of duplicative care at a multisite, multiregional cancer practice with a diverse patient population according to a study from investigators at the Mayo Clinic in Rochester, Minnesota, that looked at telehealth visits for cancer care beyond the initial expansion of telehealth during the COVID-19 pandemic.1 “Telehealth
-
Helping patients with cancer to understand secondary findings on genetic tests Cancer (IF 6.2) Pub Date : 2024-02-15 Mary Beth Nierengarten
Many patients with advanced-stage cancer who undergo tumor genomic sequencing are grateful to learn about possible germline inherited cancer risk, as it helps them and their families to better prepare for the future. Pretest counseling and education for tumor sequencing are highly variable, however, even though they can significantly benefit patients by helping them to understand and prepare for the
-
A local perspective on internal, external, and reflexive biomarker testing processes for lung cancer in an academic medical center Cancer (IF 6.2) Pub Date : 2024-02-14 Andrea M. Russell, Allison P. Pack, Stacy C. Bailey, Christine B. Weldon, Marie S. Dreyer, Sheetal M. Kircher, Michael S. Wolf
In a large academic medical center, processes for ordering and receiving biomarker testing to inform cancer treatment in nonsmall cell lung cancer varied by whether tests were conducted internally or externally. Lack of standardization in biomarker testing processes, despite the availability of electronic health record solutions, contributes to clinician burden and may increase risk of delays in receipt
-
Cumulative incidence and risk factors of brain metastases in metastatic non–small cell lung cancer without baseline brain metastasis: Pooled analysis of individualized patient data from IMpower130, IMpower131, and IMpower150 Cancer (IF 6.2) Pub Date : 2024-02-14 Yue Zhou, Tiantian Guo, Fei Liang, Zezhou Wang, Junhua Zhang, Jianjiao Ni, Zhengfei Zhu
The objective of this study was to explore the abilities of atezolizumab plus chemotherapy in preventing brain metastases (BMs) among metastatic non–small cell lung cancer (NSCLC) without initial BMs, as well as the risk factors of BMs.
-
The Prostate Cancer Active Lifestyle Study (PALS): A randomized controlled trial of diet and exercise in overweight and obese men on active surveillance Cancer (IF 6.2) Pub Date : 2024-02-14 Jonathan L. Wright, Jeannette M. Schenk, Roman Gulati, Sarah J. Beatty, Matthew VanDoren, Daniel W. Lin, Michael P. Porter, Colm Morrissey, Atreya Dash, John L. Gore, Ruth Etzioni, Stephen R. Plymate, Marian L. Neuhouser
Active surveillance (AS) is increasingly used to monitor patients with lower risk prostate cancer (PCa). The Prostate Cancer Active Lifestyle Study (PALS) was a randomized controlled trial to determine whether weight loss improves obesity biomarkers on the causal pathway to progression in patients with PCa on AS.
-
Time to Be Launched 1 auXiliary Risk strat1fier in marginal zone lymphoma transformation: TBL1XR1 Cancer (IF 6.2) Pub Date : 2024-02-14 Alexandar Tzankov, Maciej Tatarczuch
The genetic profile of lymphomas has an increasing role in diagnosis, prognostication, and therapeutic decision making. In this issue of Cancer, Li and colleagues provide insights into the genomic landscape of high-grade transformation of marginal zone lymphoma compared with both, indolent marginal zone lymphoma and de novo diffuse large B-cell lymphoma.
-
Examining crossover and postprotocol therapies in first-line immunotherapy trials in non–small cell lung cancer (NSCLC) Cancer (IF 6.2) Pub Date : 2024-02-14 Aakash Desai, Caleb J. Smith, Joshua C. Pritchett, Konstantinos Leventakos, Howard (Jack) West
Immune checkpoint inhibitor (ICI) therapy has led to significant improvement in outcomes for patients with nononcogene-driven advanced non–small cell lung cancer (NSCLC). The rate of crossover and receipt of postprotocol ICI in frontline trials for advanced NSCLC has not been systematically evaluated.
-
Plant-based diet associated with better quality of life in prostate cancer survivors Cancer (IF 6.2) Pub Date : 2024-02-13 Stacy Loeb, Qi Hua, Scott R. Bauer, Stacey A. Kenfield, Alicia K. Morgans, June M. Chan, Erin L. Van Blarigan, Alaina H. Shreves, Lorelei A. Mucci
Plant-based diets have many health benefits, including a lower risk of fatal prostate cancer, and greater environmental sustainability. However, less is known regarding the impact of plant-based diets on quality of life among individuals diagnosed with prostate cancer. The authors' objective was to examine the relationship between plant-based diet indices postdiagnosis with quality of life.
-
Physical activity and pain in people with and without cancer Cancer (IF 6.2) Pub Date : 2024-02-12 Christopher T. V. Swain, Matthew Masters, Brigid M. Lynch, Alpa V. Patel, Erika Rees-Punia
Performing physical activity may provide analgesic benefit, although this effect is more established for noncancer pain rather than cancer pain. The relationship between physical activity and pain outcomes in adults with and without a history of cancer was examined.
-
Safety and effectiveness of the radium-223–taxane treatment sequence in patients with metastatic castration-resistant prostate cancer in a global observational study (REASSURE) Cancer (IF 6.2) Pub Date : 2024-02-10 Celestia S. Higano, Sabina Dizdarevic, John Logue, Timothy Richardson, Saby George, Igle de Jong, Jeffrey J. Tomaszewski, Fred Saad, Kurt Miller, Jeffrey Meltzer, Per Sandström, Frank Verholen, Bertrand Tombal, Oliver Sartor
-
Challenges in clinical trials for high-risk but curable prostate cancer Cancer (IF 6.2) Pub Date : 2024-02-10 Tanya Barauskas Dorff, Alan H. Bryce
Clinical trials studying neoadjuvant and adjuvant therapy around prostatectomy for patients with high-risk prostate cancer have faced multiple challenges. Patients who have a very good response to neoadjuvant therapy may not wish to continue to adjuvant treatment, and prostate-specific antigen–based end points are difficult to interpret because of variations in testosterone recovery.
-
Ivosidenib significantly reduces triazole levels in patients with acute myeloid leukemia and myelodysplastic syndrome Cancer (IF 6.2) Pub Date : 2024-02-10 Ashley Dinh, J. Michael Savoy, Dimitrios P. Kontoyiannis, Koichi Takahashi, Ghayas C. Issa, Hagop M. Kantarjian, Courtney D. DiNardo, Caitlin R. Rausch
Ivosidenib is primarily metabolized by CYP3A4; however, it induces CYP450 isozymes, including CYP3A4 and CYP2C9, whereas it inhibits drug transporters, including P-glycoprotein. Patients with acute myeloid leukemia are at risk of invasive fungal infections, and therefore posaconazole and voriconazole are commonly used in this population. Voriconazole is a substrate of CYP2C9, CYP2C19, and CYP3A4; therefore
-
-
First person profile: Michelle M. Le Beau, PhD Cancer (IF 6.2) Pub Date : 2024-02-08 Mary Beth Nierengarten
This news section offers Cancer readers timely information on events, public policy analysis, topical issues, and personalities. In this issue, the life-long fascination with cancer cytogenetics of Michelle M. Le Beau, PhD, has contributed to vast improvements in the treatment of certain cancers based on genetic subgroups. In addition, two studies show benefits for patients with resectable non-small
-
Phase 3 AEGEAN trial results show the benefit of perioperative immunotherapy-based treatment for NSCLC Cancer (IF 6.2) Pub Date : 2024-02-08 Mary Beth Nierengarten
Phase 3 results from the AEGEAN trial show that patients with resectable non–small cell lung cancer (NSCLC) treated with perioperative durvalumab in addition to chemotherapy had significantly improved event-free survival (EFS) and rates of pathologic complete response (pCR) as compared to patients treated with chemotherapy alone.1 First presented at the 2023 American Association for Cancer Research
-
Improved progression-free survival, increased toxicities seen with amivantamab for EGFR-mutant NSCLC Cancer (IF 6.2) Pub Date : 2024-02-08 Mary Beth Nierengarten
Patients with EGFR-mutant non–small cell lung cancer (NSCLC) soon may have another option for first- and second-line treatments involving amivantamab combination regimens, according to the positive results of two phase 3 trials recently presented at the 2023 European Society for Medical Oncology Congress in October.1, 2 Results of the MARIPOSA and MARIPOSA-2 trials showed that the addition of amivantamab